Research and Clinical Trials

Title  
Janssen 63935937MDS3001: A Study to Evaluate Imetelstat (JNJ63935937) in Transfision-DependentSubjects with IPSS Low or Intermediate-I Risk Myelodysplastic Syndrom (MDS) that is Relapsed/ Refractory to Erythropoiesis-Stemulating Agent (ESA) Treatment
Brief Description  
Primary Part I: Evaluate efficacy and safety of imetelstat in transfusion dependent subjects with low/ intermediate-I risk MDS that is relapsed/ refratory to ESA treatment. Part I: To compare the efficacy, in terms of red blood cell (RBC) transfusion independence (TI), of imetelstat to placebo in tranfusion dependent subjects with low or intermediate-I risk MDS that is relapsed/ refractory to ESA treatment.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Myeloid and Monocytic Leukemia
Status  
OPEN
Start Date  
04/19/2016
IRB Number  
00016752
Principal Investigator  
Grunwald, Michael Richard
Contact Name  
Mallory Tucker

For More Information, Contact  Mallory  , Tucker
Phone:  980-442-2011 Fax:    
Email:  Mallory.Rodgers@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close